Iran has been importing Ibrutinib up to now, but the drug’s production has now been indiginized thanks to specialists of a knowledge-based company, IRNA reported on Saturday.
After five years of intensive research and passing production phases, the drug is now ready for patient use.
With the achievement, Iran becomes one of the three countries in the world possessing the technical knowledge to produce the primary material for Ibrutinib, after India and China.
The actual global market value of this drug exceeds $10 billion, officials said.
Ibrutinib is used to treat blood cancers and lymphomas, inhibiting a disease-causing enzyme and impeding the growth of cancer cells.
4353**2050
Your Comment